Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Altimmune, Inc.ALT · Entity 5349 | Director | August 19, 2024 | August 20, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Altimmune, Inc.
Report date August 19, 2024 · Filed August 20, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.0001SEC Table I · non-derivative | IndirectSee Footnote | 55,524 |
Last balance in matching sequence
After 2024-08-19 transaction · row 4
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
4 source rowsRow 1 · 2024-08-19 · Exercise / conversion · Acquired 20,000 · Balance 49,785 F1: Shares received upon exercise were immediately transferred to Pacific Biopharma Associates, LLC. F2: Represents Common Stock held by Pacific Biopharma Associates, LLC, of which the reporting person is the President. Row 2 · 2024-08-19 · Sale · Disposed 7,827 · Balance 41,958 F3: This sale represents shares sold to cover the exercise price. F2: Represents Common Stock held by Pacific Biopharma Associates, LLC, of which the reporting person is the President. Row 3 · 2024-08-19 · Exercise / conversion · Acquired 21,750 · Balance 63,708 F1: Shares received upon exercise were immediately transferred to Pacific Biopharma Associates, LLC. F2: Represents Common Stock held by Pacific Biopharma Associates, LLC, of which the reporting person is the President. Row 4 · 2024-08-19 · Sale · Disposed 8,184 · Balance 55,524 F3: This sale represents shares sold to cover the exercise price. F2: Represents Common Stock held by Pacific Biopharma Associates, LLC, of which the reporting person is the President. |
| Stock Options (option to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.60 · Expires 2029-01-02 | Direct | 0 |
Reported balance
After 2024-08-19 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2024-08-19 · Exercise / conversion · Disposed 20,000 · Balance 0 F4: The shares underlying the option became vested and exercisable in two equal installments on February 28, 2019 and August 30, 2019, in each case, generally subject to the reporting person's continued service through the applicable vesting date. |
| Stock Options (option to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.50 · Expires 2033-09-28 | Direct | 4,350 |
Reported balance
After 2024-08-19 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2024-08-19 · Exercise / conversion · Disposed 21,750 · Balance 4,350 F5: The shares underlying the option became vested and exercisable in substantially equal monthly installments over the 12 months following September 28, 2023, subject to the reporting person's continued service through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares received upon exercise were immediately transferred to Pacific Biopharma Associates, LLC.
F2: Represents Common Stock held by Pacific Biopharma Associates, LLC, of which the reporting person is the President.
F3: This sale represents shares sold to cover the exercise price.
F4: The shares underlying the option became vested and exercisable in two equal installments on February 28, 2019 and August 30, 2019, in each case, generally subject to the reporting person's continued service through the applicable vesting date.
F5: The shares underlying the option became vested and exercisable in substantially equal monthly installments over the 12 months following September 28, 2023, subject to the reporting person's continued service through the applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 19, 2024 Filed Aug 20, 2024 18:05 UTC | Altimmune, Inc. ALT · Entity 5349 | Exercise / conversionStock Options (option to buy) · Derivative | 21,750 | $0.00 Strike: $2.50 | $0.00 |
DisclosureSEC source: 0001104659-24-091346 · tm2422185-1_4seq1.xml · derivative · entry 6 Drutz David · CIK 0001428764 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,350 Underlying: Common Stock, par value $0.0001 · 21,750 shares Expires 2033-09-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The shares underlying the option became vested and exercisable in substantially equal monthly installments over the 12 months following September 28, 2023, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| August 19, 2024 Filed Aug 20, 2024 18:05 UTC | Altimmune, Inc. ALT · Entity 5349 | Exercise / conversionStock Options (option to buy) · Derivative | 20,000 | $0.00 Strike: $2.60 | $0.00 |
DisclosureSEC source: 0001104659-24-091346 · tm2422185-1_4seq1.xml · derivative · entry 5 Drutz David · CIK 0001428764 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, par value $0.0001 · 20,000 shares Expires 2029-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares underlying the option became vested and exercisable in two equal installments on February 28, 2019 and August 30, 2019, in each case, generally subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| August 19, 2024 Filed Aug 20, 2024 18:05 UTC | Altimmune, Inc. ALT · Entity 5349 | SaleCommon Stock, par value $0.0001 | 8,184 | $6.88 | $56,305.92 |
DisclosureSEC source: 0001104659-24-091346 · tm2422185-1_4seq1.xml · nonDerivative · entry 4 Drutz David · CIK 0001428764 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 55,524 F3 · shares: This sale represents shares sold to cover the exercise price. F2 · ownership.nature: Represents Common Stock held by Pacific Biopharma Associates, LLC, of which the reporting person is the President. Read SEC document |
| August 19, 2024 Filed Aug 20, 2024 18:05 UTC | Altimmune, Inc. ALT · Entity 5349 | Exercise / conversionCommon Stock, par value $0.0001 | 21,750 | $2.50 | $54,375.00 |
DisclosureSEC source: 0001104659-24-091346 · tm2422185-1_4seq1.xml · nonDerivative · entry 3 Drutz David · CIK 0001428764 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 63,708 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares received upon exercise were immediately transferred to Pacific Biopharma Associates, LLC. F2 · ownership.nature: Represents Common Stock held by Pacific Biopharma Associates, LLC, of which the reporting person is the President. Read SEC document |
| August 19, 2024 Filed Aug 20, 2024 18:05 UTC | Altimmune, Inc. ALT · Entity 5349 | SaleCommon Stock, par value $0.0001 | 7,827 | $6.93 | $54,241.11 |
DisclosureSEC source: 0001104659-24-091346 · tm2422185-1_4seq1.xml · nonDerivative · entry 2 Drutz David · CIK 0001428764 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 41,958 F3 · shares: This sale represents shares sold to cover the exercise price. F2 · ownership.nature: Represents Common Stock held by Pacific Biopharma Associates, LLC, of which the reporting person is the President. Read SEC document |
| August 19, 2024 Filed Aug 20, 2024 18:05 UTC | Altimmune, Inc. ALT · Entity 5349 | Exercise / conversionCommon Stock, par value $0.0001 | 20,000 | $2.60 | $52,000.00 |
DisclosureSEC source: 0001104659-24-091346 · tm2422185-1_4seq1.xml · nonDerivative · entry 1 Drutz David · CIK 0001428764 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 49,785 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares received upon exercise were immediately transferred to Pacific Biopharma Associates, LLC. F2 · ownership.nature: Represents Common Stock held by Pacific Biopharma Associates, LLC, of which the reporting person is the President. Read SEC document |
| September 28, 2023 Filed Sep 29, 2023 17:01 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantStock Options (option to buy) · Derivative | 26,100 | $0.00 Strike: $2.50 | $0.00 |
DisclosureSEC source: 0001104659-23-105401 · tm2327241-7_4seq1.xml · derivative · entry 1 Drutz David · CIK 0001428764 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,100 Underlying: Common Stock, par value $0.0001 · 26,100 shares Expires 2033-09-28 F1 · derivative.exercise_date: The shares underlying the option become vested and exercisable in substantially equal monthly installments over the 12 months following September 28, 2023, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| August 15, 2023 Filed Aug 15, 2023 18:46 UTC | Altimmune, Inc. ALT · Entity 5349 | PurchaseCommon Stock, par value $0.0001 | 300 | $2.88 | $862.50 |
DisclosureSEC source: 0001104659-23-092080 · tm2323899-1_4seq1.xml · nonDerivative · entry 1 Drutz David · CIK 0001428764 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 29,785 F1 · shares: Represents Common Stock purchased and immediately transferred to Pacific Biopharma Associates, LLC. F2 · ownership.nature: Represents Common Stock held by Pacific Biopharma Associates, LLC, of which the reporting person is the President. Read SEC document |
| March 23, 2023 Filed Mar 27, 2023 17:17 UTC | Altimmune, Inc. ALT · Entity 5349 | PurchaseCommon Stock, par value $0.0001 | 9,000 | $4.27 | $38,430.00 |
DisclosureSEC source: 0001104659-23-037190 · tm2310588d1_4seq1.xml · nonDerivative · entry 1 Drutz David · CIK 0001428764 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 29,484 F1 · shares: Represents Common Stock purchased and immediately transferred to Pacific Biopharma Associates, LLC. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.265 to $4.28, inclusive. The reporting person undertakes to provide to Altimmune, Inc., any security holder of Altimmune, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F3 · balance_after: Includes 20,151 shares of Common Stock previously owned directly by the reporting person which were transferred to Pacific Biopharma Associates, LLC. F4 · ownership.nature: Represents Common Stock held by Pacific Biopharma Associates, LLC, of which the reporting person is the President. Read SEC document |
| November 18, 2022 Filed Nov 21, 2022 16:05 UTC | Altimmune, Inc. ALT · Entity 5349 | Exercise / conversionStock Options (option to buy) · Derivative | 139 | $0.00 Strike: $2.40 | $0.00 |
DisclosureSEC source: 0001104659-22-120752 · tm2231089-1_4seq1.xml · derivative · entry 3 Drutz David · CIK 0001428764 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, par value $0.0001 · 139 shares Expires 2022-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: This option was previously reported as covering 4,178 shares at an exercise price of $0.08 per share, but was adjusted to reflect a one-for-thirty reverse stock split that occurred on September 13, 2018. F2 · shares: This option was previously reported as covering 4,178 shares at an exercise price of $0.08 per share, but was adjusted to reflect a one-for-thirty reverse stock split that occurred on September 13, 2018. F3 · derivative.exercise_date: This option is fully vested and exercisable as of the date hereof. F2 · derivative.underlying_shares: This option was previously reported as covering 4,178 shares at an exercise price of $0.08 per share, but was adjusted to reflect a one-for-thirty reverse stock split that occurred on September 13, 2018. Read SEC document |
| November 18, 2022 Filed Nov 21, 2022 16:05 UTC | Altimmune, Inc. ALT · Entity 5349 | Exercise / conversionCommon Stock, par value $0.0001 | 139 | $2.40 | $333.60 |
DisclosureSEC source: 0001104659-22-120752 · tm2231089-1_4seq1.xml · nonDerivative · entry 1 Drutz David · CIK 0001428764 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,151 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 29, 2022 Filed Sep 30, 2022 21:22 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantStock Options (option to buy) · Derivative | 23,500 | $0.00 Strike: $12.62 | $0.00 |
DisclosureSEC source: 0001104659-22-104780 · tm2227177-6_4seq1.xml · derivative · entry 1 Drutz David · CIK 0001428764 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,500 Underlying: Common Stock, par value $0.0001 · 23,500 shares Expires 2032-09-29 F1 · derivative.exercise_date: The shares underlying the option become vested and exercisable in substantially equal monthly installments over the 12 months following September 29, 2022, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| June 15, 2022 Filed Jun 16, 2022 21:27 UTC | Altimmune, Inc. ALT · Entity 5349 | PurchaseCommon Stock, par value $0.0001 | 1,000 | $8.00 | $8,000.00 |
DisclosureSEC source: 0001104659-22-072059 · tm2218746d1_4.xml · nonDerivative · entry 1 Drutz David · CIK 0001428764 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,012 Read SEC document |
| May 24, 2022 Filed May 25, 2022 19:00 UTC | Altimmune, Inc. ALT · Entity 5349 | PurchaseCommon Stock, par value $0.0001 | 1,200 | $4.50 | $5,400.00 |
DisclosureSEC source: 0001104659-22-064786 · tm2216827-1_4seq1.xml · nonDerivative · entry 1 Drutz David · CIK 0001428764 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,012 Read SEC document |
| January 25, 2022 Filed Jan 26, 2022 19:00 UTC | Altimmune, Inc. ALT · Entity 5349 | Exercise / conversionStock Options (option to buy) · Derivative | 70 | $0.00 Strike: $2.40 | $0.00 |
DisclosureSEC source: 0001104659-22-007911 · tm224587-1_4.xml · derivative · entry 3 Drutz David · CIK 0001428764 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69 Underlying: Common Stock, par value $0.0001 · 70 shares Expires 2022-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: This option was previously reported as covering 4,178 shares at an exercise price of $0.08 per share, but was adjusted to reflect a one-for-thirty reverse stock split reverse stock split that occurred on September 13, 2018. F2 · shares: This option was previously reported as covering 4,178 shares at an exercise price of $0.08 per share, but was adjusted to reflect a one-for-thirty reverse stock split reverse stock split that occurred on September 13, 2018. F3 · derivative.exercise_date: This option is fully vested and exercisable as of the date hereof. F2 · derivative.underlying_shares: This option was previously reported as covering 4,178 shares at an exercise price of $0.08 per share, but was adjusted to reflect a one-for-thirty reverse stock split reverse stock split that occurred on September 13, 2018. Read SEC document |
| January 25, 2022 Filed Jan 26, 2022 19:00 UTC | Altimmune, Inc. ALT · Entity 5349 | Exercise / conversionCommon Stock, par value $0.0001 | 70 | $2.40 | $168.00 |
DisclosureSEC source: 0001104659-22-007911 · tm224587-1_4.xml · nonDerivative · entry 1 Drutz David · CIK 0001428764 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,882 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 14, 2021 Filed Dec 15, 2021 19:00 UTC | Altimmune, Inc. ALT · Entity 5349 | Exercise / conversionStock Options (option to buy) · Derivative | 139 | $0.00 Strike: $2.40 | $0.00 |
DisclosureSEC source: 0001104659-21-150119 · tm2135595-1_4seq1.xml · derivative · entry 3 Drutz David · CIK 0001428764 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, par value $0.0001 · 139 shares Expires 2022-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: This option was previously reported as covering 4,178 shares at an exercise price of $0.08 per share, but was adjusted to reflect a one-for-thirty reverse stock split reverse stock split that occurred on September 13, 2018. F2 · shares: This option was previously reported as covering 4,178 shares at an exercise price of $0.08 per share, but was adjusted to reflect a one-for-thirty reverse stock split reverse stock split that occurred on September 13, 2018. F3 · derivative.exercise_date: This option is fully vested and exercisable as of the date hereof. F2 · derivative.underlying_shares: This option was previously reported as covering 4,178 shares at an exercise price of $0.08 per share, but was adjusted to reflect a one-for-thirty reverse stock split reverse stock split that occurred on September 13, 2018. Read SEC document |
| December 14, 2021 Filed Dec 15, 2021 19:00 UTC | Altimmune, Inc. ALT · Entity 5349 | Exercise / conversionCommon Stock, par value $0.0001 | 139 | $2.40 | $333.60 |
DisclosureSEC source: 0001104659-21-150119 · tm2135595-1_4seq1.xml · nonDerivative · entry 1 Drutz David · CIK 0001428764 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,812 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 19, 2021 Filed Nov 19, 2021 19:00 UTC | Altimmune, Inc. ALT · Entity 5349 | Exercise / conversionStock Options (option to buy) · Derivative | 70 | $0.00 Strike: $2.40 | $0.00 |
DisclosureSEC source: 0001104659-21-142052 · tm2133565-1_4seq1.xml · derivative · entry 3 Drutz David · CIK 0001428764 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, par value $0.0001 · 70 shares Expires 2021-12-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: This option was previously reported as covering 2,090 shares at an exercise price of $0.08 per share, but was adjusted to reflect a one-for-thirty reverse stock split reverse stock split that occurred on September 13, 2018. F2 · shares: This option was previously reported as covering 2,090 shares at an exercise price of $0.08 per share, but was adjusted to reflect a one-for-thirty reverse stock split reverse stock split that occurred on September 13, 2018. F3 · derivative.exercise_date: This option is fully vested and exercisable as of the date hereof. F2 · derivative.underlying_shares: This option was previously reported as covering 2,090 shares at an exercise price of $0.08 per share, but was adjusted to reflect a one-for-thirty reverse stock split reverse stock split that occurred on September 13, 2018. Read SEC document |
| November 19, 2021 Filed Nov 19, 2021 19:00 UTC | Altimmune, Inc. ALT · Entity 5349 | Exercise / conversionCommon Stock, par value $0.0001 | 70 | $2.40 | $168.00 |
DisclosureSEC source: 0001104659-21-142052 · tm2133565-1_4seq1.xml · nonDerivative · entry 1 Drutz David · CIK 0001428764 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,673 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 23, 2021 Filed Sep 24, 2021 20:45 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantStock Options (option to buy) · Derivative | 24,100 | $0.00 Strike: $15.44 | $0.00 |
DisclosureSEC source: 0001104659-21-119482 · tm2128463-1_4seq1.xml · derivative · entry 1 Drutz David · CIK 0001428764 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,100 Underlying: Common Stock, par value $0.0001 · 24,100 shares Expires 2031-09-23 F1 · derivative.exercise_date: The shares underlying the option become vested and exercisable in substantially equal monthly installments over the 12 months following September 23, 2021, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| November 13, 2020 Filed Nov 17, 2020 19:00 UTC | Altimmune, Inc. ALT · Entity 5349 | Exercise / conversionStock Options (option to buy) · Derivative | 60 | $0.00 Strike: $2.40 | $0.00 |
DisclosureSEC source: 0000899243-20-031318 · doc4.xml · derivative · entry 3 Drutz David · CIK 0001428764 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 60 shares Expires 2020-12-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: This option was previously reported as covering 1,791 shares at an exercise price of $0.08 per share, but was adjusted to reflect a one-for-thirty reverse stock split reverse stock split that occurred on September 7, 2018. F1 · derivative.exercise_date: This option was previously reported as covering 1,791 shares at an exercise price of $0.08 per share, but was adjusted to reflect a one-for-thirty reverse stock split reverse stock split that occurred on September 7, 2018. Read SEC document |
| November 13, 2020 Filed Nov 17, 2020 19:00 UTC | Altimmune, Inc. ALT · Entity 5349 | Exercise / conversionCommon Stock, par value $0.0001 | 60 | $2.40 | $144.00 |
DisclosureSEC source: 0000899243-20-031318 · doc4.xml · nonDerivative · entry 1 Drutz David · CIK 0001428764 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,603 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 24, 2020 Filed Sep 28, 2020 18:00 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantStock Options (option to buy) · Derivative | 25,500 | $0.00 Strike: $12.03 | $0.00 |
DisclosureSEC source: 0000899243-20-026411 · doc4.xml · derivative · entry 1 Drutz David · CIK 0001428764 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,500 Underlying: Common Stock, par value $0.0001 · 25,500 shares Expires 2030-09-24 F1 · derivative.exercise_date: The shares underlying the option become vested and exercisable in substantially equal monthly installments over the 12 months following September 24, 2020, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| September 24, 2020 Filed Oct 16, 2020 19:00 UTC | Altimmune, Inc. ALT · Entity 5349 | Exercise / conversionRestricted Stock Units ("RSUs") · Derivative | 16,850 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-028538 · doc4.xml · derivative · entry 3 Drutz David · CIK 0001428764 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,850 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. F3 · derivative.exercise_date: On June 25, 2020, the reporting person was granted 16,850 restricted stock units, which vested in full at the Company's 2020 annual meeting of stockholders on September 24, 2020. F3 · derivative.expiration_date: On June 25, 2020, the reporting person was granted 16,850 restricted stock units, which vested in full at the Company's 2020 annual meeting of stockholders on September 24, 2020. Read SEC document |
| September 24, 2020 Filed Oct 16, 2020 19:00 UTC | Altimmune, Inc. ALT · Entity 5349 | Exercise / conversionCommon Stock, par value $0.0001 | 16,850 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-028538 · doc4.xml · nonDerivative · entry 1 Drutz David · CIK 0001428764 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,543 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 25, 2020 Filed Jun 29, 2020 21:54 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantRestricted Stock Units ("RSUs") · Derivative | 16,850 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-017835 · doc4.xml · derivative · entry 1 Drutz David · CIK 0001428764 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,850 Underlying: Common Stock · 16,850 shares Expires not disclosed F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. F2 · derivative.exercise_date: The RSUs vest in full at the Company's 2020 annual meeting of stockholders, subject to the reporting person's continued service through the vesting date, and have no expiration date. F2 · derivative.expiration_date: The RSUs vest in full at the Company's 2020 annual meeting of stockholders, subject to the reporting person's continued service through the vesting date, and have no expiration date. Read SEC document |
| January 02, 2019 Filed Jan 4, 2019 17:07 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantStock Options (option to buy) · Derivative | 20,000 | $0.00 Strike: $2.60 | $0.00 |
DisclosureSEC source: 0001012975-19-000033 · edgar.xml · derivative · entry 1 Drutz David · CIK 0001428764 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock, par value $0.0001 · 20,000 shares Expires 2029-01-02 F1 · derivative.exercise_date: The option becomes vested and exercisable in two equal installments on February 28, 2019 and August 30, 2019, in each case, generally subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| October 13, 2017 Filed Oct 17, 2017 20:07 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantStock Options (option to buy) · Derivative | 20,000 | $0.00 Strike: $2.50 | $0.00 |
DisclosureSEC source: 0001012975-17-000761 · edgar.xml · derivative · entry 1 Drutz David · CIK 0001428764 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock, par value $0.0001 · 20,000 shares Expires 2027-10-13 Read SEC document |
| August 23, 2017 Filed Aug 24, 2017 16:48 UTC | Altimmune, Inc. ALT · Entity 5349 | PurchaseCommon Stock, par value $0.0001 | 5,000 | $2.27 | $11,339.50 |
DisclosureSEC source: 0001012975-17-000656 · edgar.xml · nonDerivative · entry 2 Drutz David · CIK 0001428764 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,777 F2 · price: The price reflected is the weighted-average purchase price for shares purchased. The range of purchase prices for the transactions reported was $2.23 to $2.28 per share. The Reporting Person undertakes to provide, upon request by the Issuer, any security holder of the Issuer, or the SEC staff, full information regarding the number of shares purchased at each separate price. Read SEC document |
| August 22, 2017 Filed Aug 24, 2017 16:48 UTC | Altimmune, Inc. ALT · Entity 5349 | PurchaseCommon Stock, par value $0.0001 | 5,000 | $2.15 | $10,757.50 |
DisclosureSEC source: 0001012975-17-000656 · edgar.xml · nonDerivative · entry 1 Drutz David · CIK 0001428764 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,777 F1 · price: The price reflected is the weighted-average purchase price for shares purchased. The range of purchase prices for the transactions reported was $2.08 to $2.16 per share. The Reporting Person undertakes to provide, upon request by the Issuer, any security holder of the Issuer, or the SEC staff, full information regarding the number of shares purchased at each separate price. Read SEC document |
| May 04, 2017 Filed May 8, 2017 20:31 UTC | Altimmune, Inc. NASDAQ:ALT · Entity 5349 | GrantStock Option (option to buy) · Derivative | 4,177 | Not disclosed Strike: $0.59 | Not disclosed |
DisclosureSEC source: 0000899243-17-012354 · doc4.xml · derivative · entry 8 Drutz David · CIK 0001428764 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,177 Underlying: Common Stock, par value $0.0001 · 4,177 shares Expires 2022-12-31 F2 · price: Pursuant to the terms of the Merger Agreement, the Issuer assumed all outstanding options to purchase shares of Altimmune capital stock on a 0.749106:1 basis upon closing of the merger. Read SEC document |
| May 04, 2017 Filed May 8, 2017 20:31 UTC | Altimmune, Inc. NASDAQ:ALT · Entity 5349 | GrantStock Option (option to buy) · Derivative | 4,178 | Not disclosed Strike: $0.08 | Not disclosed |
DisclosureSEC source: 0000899243-17-012354 · doc4.xml · derivative · entry 7 Drutz David · CIK 0001428764 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,178 Underlying: Common Stock, par value $0.0001 · 4,178 shares Expires 2022-12-31 F2 · price: Pursuant to the terms of the Merger Agreement, the Issuer assumed all outstanding options to purchase shares of Altimmune capital stock on a 0.749106:1 basis upon closing of the merger. Read SEC document |
| May 04, 2017 Filed May 8, 2017 20:31 UTC | Altimmune, Inc. NASDAQ:ALT · Entity 5349 | GrantStock Option (option to buy) · Derivative | 4,178 | Not disclosed Strike: $0.08 | Not disclosed |
DisclosureSEC source: 0000899243-17-012354 · doc4.xml · derivative · entry 6 Drutz David · CIK 0001428764 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,178 Underlying: Common Stock, par value $0.0001 · 4,178 shares Expires 2022-01-03 F2 · price: Pursuant to the terms of the Merger Agreement, the Issuer assumed all outstanding options to purchase shares of Altimmune capital stock on a 0.749106:1 basis upon closing of the merger. Read SEC document |
| May 04, 2017 Filed May 8, 2017 20:31 UTC | Altimmune, Inc. NASDAQ:ALT · Entity 5349 | GrantStock Option (option to buy) · Derivative | 2,090 | Not disclosed Strike: $0.08 | Not disclosed |
DisclosureSEC source: 0000899243-17-012354 · doc4.xml · derivative · entry 5 Drutz David · CIK 0001428764 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,090 Underlying: Common Stock, par value $0.0001 · 2,090 shares Expires 2021-12-03 F2 · price: Pursuant to the terms of the Merger Agreement, the Issuer assumed all outstanding options to purchase shares of Altimmune capital stock on a 0.749106:1 basis upon closing of the merger. Read SEC document |
| May 04, 2017 Filed May 8, 2017 20:31 UTC | Altimmune, Inc. NASDAQ:ALT · Entity 5349 | GrantStock Option (option to buy) · Derivative | 1,791 | Not disclosed Strike: $0.08 | Not disclosed |
DisclosureSEC source: 0000899243-17-012354 · doc4.xml · derivative · entry 4 Drutz David · CIK 0001428764 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,791 Underlying: Common Stock, par value $0.0001 · 1,791 shares Expires 2020-12-30 F2 · price: Pursuant to the terms of the Merger Agreement, the Issuer assumed all outstanding options to purchase shares of Altimmune capital stock on a 0.749106:1 basis upon closing of the merger. Read SEC document |
| May 04, 2017 Filed May 8, 2017 20:31 UTC | Altimmune, Inc. NASDAQ:ALT · Entity 5349 | GrantStock Option (option to buy) · Derivative | 1,791 | Not disclosed Strike: $0.08 | Not disclosed |
DisclosureSEC source: 0000899243-17-012354 · doc4.xml · derivative · entry 3 Drutz David · CIK 0001428764 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,791 Underlying: Common Stock, par value $0.0001 · 1,791 shares Expires 2020-06-08 F2 · price: Pursuant to the terms of the Merger Agreement, the Issuer assumed all outstanding options to purchase shares of Altimmune capital stock on a 0.749106:1 basis upon closing of the merger. Read SEC document |
| May 04, 2017 Filed May 8, 2017 20:31 UTC | Altimmune, Inc. NASDAQ:ALT · Entity 5349 | GrantStock Option (option to buy) · Derivative | 4,755 | Not disclosed Strike: $0.08 | Not disclosed |
DisclosureSEC source: 0000899243-17-012354 · doc4.xml · derivative · entry 2 Drutz David · CIK 0001428764 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,755 Underlying: Common Stock, par value $0.0001 · 4,755 shares Expires 2020-06-08 F2 · price: Pursuant to the terms of the Merger Agreement, the Issuer assumed all outstanding options to purchase shares of Altimmune capital stock on a 0.749106:1 basis upon closing of the merger. Read SEC document |
| May 04, 2017 Filed May 8, 2017 20:31 UTC | Altimmune, Inc. NASDAQ:ALT · Entity 5349 | GrantCommon Stock, par value $0.0001 | 20,777 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-17-012354 · doc4.xml · nonDerivative · entry 1 Drutz David · CIK 0001428764 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,777 F1 · price: Acquired pursuant to the Agreement and Plan of Merger, dated as of January 18, 2017 (as amended on March 29, 2017, the "Merger Agreement"), pursuant to which a wholly-owned subsidiary of the Issuer merged with and into Altimmune, Inc. ("Altimmune"). Pursuant to the Merger Agreement, the then outstanding shares of Altimmune's capital stock was converted into the right to receive a number of shares of the Issuer's common stock, par value $0.0001 on a 0.749106:1 basis upon the closing of the merger. Read SEC document |
| May 04, 2017 Filed Feb 16, 2022 21:10 UTC Amendment | Altimmune, Inc. ALT · Entity 5349 | GrantStock Options (option to buy) · Derivative | 139 | Not disclosed Strike: $17.70 | Not disclosed |
DisclosureSEC source: 0001104659-22-024420 · tm226968-1_4a.xml · derivative · entry 3 Drutz David · CIK 0001428764 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139 Underlying: Common Stock, par value $0.0001 · 139 shares Expires 2023-12-31 F3 · price: Pursuant to the terms of the Agreement and Plan of Merger, dated as of January 18, 2017, as amended on March 29, 2017, the Issuer assumed all outstanding options to purchase shares of Altimmune, Inc. capital stock on a 0.749106:1 basis upon closing of the merger. F2 · derivative.expiration_date: The reporting person holds a stock option granted on May 4, 2017 for 139 shares of common stock with an exercise price of $17.7 per share and an expiration date of December 31, 2023 (the "2023 Stock Option"). The 2023 Stock Option was previously reported as covering 4,177 shares at an exercise price of $0.59 per share, but was adjusted to reflect a one-for-thirty reverse stock split that occurred on September 13, 2018. On May 4, 2017, the reporting person mistakenly filed a Form 4 reporting that the 2023 Stock Option had an expiration date of December 31, 2022. The 2023 Stock Option has an expiration date of December 31, 2023. Read SEC document |
| May 04, 2017 Filed Feb 16, 2022 21:10 UTC Amendment | Altimmune, Inc. ALT · Entity 5349 | GrantStock Options (option to buy) · Derivative | 139 | Not disclosed Strike: $2.40 | Not disclosed |
DisclosureSEC source: 0001104659-22-024420 · tm226968-1_4a.xml · derivative · entry 2 Drutz David · CIK 0001428764 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139 Underlying: Common Stock, par value $0.0001 · 139 shares Expires 2022-12-31 F1 · security: The reporting person holds a stock option granted on May 4, 2017, which is exercisable for 139 shares of common stock with an exercise price of $2.40 per share and an expiration date of December 31, 2022 (the "2022 Stock Option"). The 2022 Stock Option was previously reported as covering 4,178 shares at an exercise price of $0.08 per share, but was adjusted to reflect a one-for-thirty reverse stock split that occurred on September 13, 2018. On January 26, 2022, the reporting person mistakenly filed a Form 4 reporting the exercise of the 2022 Stock Option for 70 shares of common stock. Such exercise did not occur. As of January 25, 2022, the reporting person owned only 17,812 shares of common stock and there were 139 shares of common stock unexercised and underlying the 2022 Stock Option. F3 · price: Pursuant to the terms of the Agreement and Plan of Merger, dated as of January 18, 2017, as amended on March 29, 2017, the Issuer assumed all outstanding options to purchase shares of Altimmune, Inc. capital stock on a 0.749106:1 basis upon closing of the merger. F1 · balance_after: The reporting person holds a stock option granted on May 4, 2017, which is exercisable for 139 shares of common stock with an exercise price of $2.40 per share and an expiration date of December 31, 2022 (the "2022 Stock Option"). The 2022 Stock Option was previously reported as covering 4,178 shares at an exercise price of $0.08 per share, but was adjusted to reflect a one-for-thirty reverse stock split that occurred on September 13, 2018. On January 26, 2022, the reporting person mistakenly filed a Form 4 reporting the exercise of the 2022 Stock Option for 70 shares of common stock. Such exercise did not occur. As of January 25, 2022, the reporting person owned only 17,812 shares of common stock and there were 139 shares of common stock unexercised and underlying the 2022 Stock Option. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.